STAT+: A bellwether for biosimilars: Why the new competition for Humira matters to pharma, payers, and patients
After months of anticipation, the first biosimilar version of Humira will become available next week…
Category: STAT+
HHS’ Becerra on enrolling in Medicare, annual Covid vaccines, and seniors’ mental health
WASHINGTON — The hottest birthday spot in town: A Hispanic senior center in northwest D.C….
STAT+: Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices
In her latest bid to address prescription drug prices, U.S. Sen. Elizabeth Warren (D-Mass.) is…
STAT+: Pharmalittle: Strange bedfellows lobby for Medicare coverage of obesity drugs; FDA working with WHO to probe cough syrups
Hello, everyone, and how are you this morning? We are doing just fine, thank you,…
STAT+: ChatGPT in health care: 5 burning questions about the buzzy new tool
If the buzz is to be believed, ChatGPT seems poised to upend everything from high…
STAT+: The unexpected alliance lobbying for Medicare to pay for new obesity drugs
WASHINGTON — It’s not every day that the pharmaceutical industry, the NAACP, a cancer center, and…
STAT+: Novartis and Lilly turn to nonprofit, instead of FDA, to resolve dispute over drug ad
In a rare move, the Better Business Bureau National Programs settled a dispute between two…
STAT+: Pharmalittle: Merck ends late-stage trial for Keytruda in prostate cancer; doctor group says 60 Minutes segment on Wegovy was an ad
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Vir CEO George Scangos to retire, after pandemic success
Vir Biotechnology CEO George Scangos said on Wednesday he will retire, ending an itinerant, nearly…
STAT+: Focused exclusively on life sciences, three top investors set out on their own
Almost a year ago, three top investors at Lux Capital and Obvious Ventures announced they…
STAT+: The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals
WASHINGTON — Congress just boosted the FDA’s authority over the post-market clinical trials that are…
.jpg)
STAT+: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy
Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of…
STAT+: Doctors’ group complains that 60 Minutes segment on Wegovy was really just an ad
A physicians’ group has filed a complaint with the U.S. Food and Drug Administration alleging…
STAT+: Health systems have much higher prices, only marginally better quality, new study finds
The claims have become almost ubiquitous. Hospital CEO after hospital CEO stands at a podium…
STAT+: Pharmalittle: Amazon adds $5 monthly generic drug subscription; PhRMA ends lobbying contract with brother of White House official
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Amazon Pharmacy expands with new $5 monthly prescription service
Amazon is launching a new prescription service that lets patients on Amazon Prime get eligible…
STAT+: Many pediatric drug study results were never posted to a U.S. government database
Amid ongoing controversy over clinical trial transparency, a new analysis found that results of 43…
STAT+: ‘I’m just disgusted’: How alleged sexual misconduct stole one student’s passion for academic science
It was the summer of 2020, and she couldn’t have scripted a better start as…
STAT+: Calico looking for new chief scientist after celebrated biologist David Botstein quietly retires
Are you a promising middle or late-career scientist with a desire to extend human lifespan,…
STAT+: Health groups like AHA, PhRMA channeled millions into end-of-year legislative debates
WASHINGTON — Health care groups and their lobbyists spent big in the last few months…
STAT+: Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity
In an unexpected move, the U.S. Food and Drug Administration will continue to apply exclusive…
STAT+: Pharmalittle: Obesity guidelines cause backlash; Bayer is pushed to spin off its consumer health business
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: As more never-smokers develop lung cancer, researchers test an AI model to predict patient risk
Massachusetts General Hospital is launching a prospective trial of an artificial intelligence tool designed to…
STAT+: A different kind of ‘RAC’ subsidized hospitals’ labor during the pandemic
Hospitals have bemoaned rising employee expenses throughout the pandemic, as they’ve paid workers more to…
STAT+: How one private biotech seized on JPM to emerge from stealth and tell its story
SAN FRANCISCO — The team behind Rezo Therapeutics, a new biotech co-founded by a group…
STAT+: ‘Holding on by its fingernails.’ The biotech industry in Massachusetts braces for another tough year
It’s hard to overstate the Boston biotechnology industry’s astronomical growth, which has overflowed from its…
STAT+: FTC wants ‘pharma bro’ Martin Shkreli held in contempt for violating lifelong ban on working in pharma
The U.S. Federal Trade Commission asked a federal judge to hold “pharma bro” Martin Shkreli…
STAT+: Pharmalittle: FDA rejects Lilly application for Alzheimer’s drug; Sanofi offers a warranty for a medicine
And so, another working week will soon draw to a close. Not a moment too…
STAT+: FDA rejects Lilly’s bid for accelerated approval for its Alzheimer’s drug
Eli Lilly said Thursday that U.S. regulators had rejected its application seeking accelerated approval for…
STAT+: ‘A cascade of failures’: FDA cites Indian drugmaker for numerous quality control problems
In a stunning rebuke, the U.S. Food and Drug Administration accused a drugmaker of a…
STAT+: Pallone pushes NIH and FDA to disclose steps being taken to ensure clinical trial results are reported
A Democratic lawmaker is demanding to know what steps the U.S. Food and Drug Administration…
STAT+: For only the second time, a big drugmaker offers a warranty on a medicine
In a bid to blunt competition and address rising drug costs, Sanofi is offering a…
.jpg)
STAT+: Pharmalittle: India regulator finds 5% of drug samples are substandard; EMA claims new clinical trial registry is fixed
Hello, everyone, and how are you today? A steely gray sky is hovering this morning…
STAT+: Verily leans into Onduo as it looks to enter the lucrative world of running medical research
The new, streamlined Verily will have one very recognizable component: its virtual care company Onduo,…
STAT+: Pharmalittle: HIV vaccine study is stopped early; Merck has a plan to combat carcinogen found in diabetes drugs
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Hip and knee replacements go better when performed by high-volume surgeons, new study finds
A new study underscores the importance of the adage “practice makes perfect,” especially when it…
STAT+: Major purchasers predict expensive new therapies will keep driving drug price hikes
More than two dozen big buyers of prescription medicines expect that prices will rise by…
STAT+: Moderna says RSV vaccine worked, setting stage for competition with GSK and Pfizer
Moderna’s vaccine against the respiratory syncytial virus, or RSV, reduced the rate of lower respiratory…
STAT+: After four years of big talk, mega startup Sana prepares to deliver some data
SAN FRANCISCO — The last time Sana CEO Steve Harr was here for the J.P….
STAT+: Pfizer says it will widen access to hundreds of off-patent medicines in poor countries
In another bid to widen access to its medical products, Pfizer plans to provide roughly…
STAT+: Pharmalittle: Lilly and AbbVie exit U.K. drug-pricing program; J&J scales back Covid-19 vaccine production
Good morning, everyone, and welcome to another working week, which is only getting started on…
STAT+: Large health insurers lowered barriers to fair access to some drugs, analysis finds
Most of the largest health plans in the U.S. generally provide “fair access” to 19…
Opinion: STAT+: 4 concrete steps to realize the AI Bill of Rights for clinical decision support software
The Blueprint for an AI Bill of Rights the White House recently published didn’t come…
STAT+: Hospitals gear up to expand market power, raise prices in 2023
SAN FRANCISCO — More than a dozen of the country’s large not-for-profit hospital systems descended…
STAT+: Liquid biopsy study suggests a better way to decide which colorectal cancer patients need chemo
They’re far too small to be seen by even the most sophisticated medical imaging device….
STAT+: Congressional Medicare advisers warn of higher drug prices, despite new price negotiation
WASHINGTON — Despite the pharmaceutical industry’s loud complaints to the contrary, the new law directing…
STAT+: Q&A with Carbon Health’s Myoung Cha: Why the company is changing course
SAN FRANCISCO — Carbon Health is in a turbulent time: The primary care tech company…
STAT+: Pharmalittle: Pharma prioritizes biologics over pills due to drug-pricing law; former Takeda employee accused of creating fake consulting firm
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Loan repayment program seeks to bolster infectious disease field
As part of the $1.7 trillion government spending bill that President Biden signed late last…
STAT+: Oscar Health’s CEO on post-hype health insurance and finally turning a profit
Oscar Health has excelled at one thing in particular since its inception a decade ago:…